SENS Announcements



 
21/11/2014 Sekunjalo Investments Limited - No Change Statement And Notice Of Annual General Meeting, Change Of Name Circular And Notice Of General Meeting

No Change Statement And Notice Of Annual General Meeting, Change Of Name Circular And Notice Of General Meeting

SEKUNJALO INVESTMENTS LIMITED
Incorporated in the Republic of South Africa
(Registration number: 1996/006093/06)
ISIN: ZAE000017893
JSE Share Code: SKJ
(“Sekunjalo” or “the Company”)

NO CHANGE STATEMENT AND NOTICE OF ANNUAL GENERAL MEETING
Further to the publication of the detailed results announcement
on SENS on Tuesday, 4 November 2014, of Sekunjalo’s audited
group results for the year ended 31 August 2014 (“the
Announcement”), Sekunjalo advises that its 2014 Integrated
Report, which incorporates the audited annual financial
statements for the period, is available on its website:
www.sekunjalo.com or can be obtained from the Company’s
registered office, from today, 21 November 2014, and contains no
modifications from the aforementioned SENS announcement.

NOTICE OF ANNUAL GENERAL MEETING
The notice of annual general meeting, containing the condensed
annual financial statements has been distributed to shareholders
today, 21 November 2014 and accordingly notice is hereby given
that the annual general meeting of Sekunjalo will be held at
Sekunjalo Head Office, Premier Fishing, Quay 7, East Pier, V&A
Waterfront on Thursday, 26 February 2015, at 15h00, to transact
the business as set out in the notice of annual general meeting.

The date on which shareholders must be recorded in the share
register for purposes of being entitled to attend and vote at
the annual general meeting is Friday, 20 February 2015, with the
last day to trade being Friday, 13 February 2015.

CHANGE OF NAME CIRCULAR AND NOTICE OF GENERAL MEETING
Shareholders are referred to the Announcement regarding the
proposed change of name of the Company to African Equity
Empowerment Investments Limited, subject to shareholder approval
at a general meeting ("Proposed Change of Name").

Shareholders are advised that a circular detailing the Proposed
Change of Name has been posted to shareholders of Sekunjalo
(“the Circular”) today, 21 November 2014. A general meeting
convened in terms of the Circular shall be held at Sekunjalo
Head Office, Premier Fishing, Quay 7, East Pier, V&A Waterfront
on Thursday, 26 February 2015, at 14h45 (“the General Meeting”).

All salient dates and times in this regard are given below:

Record date to determine which Friday, 14 November 2014
shareholders are eligible to
receive the Circular
Circular posted to shareholders on Friday, 21 November 2014
Last day to trade in order to vote Friday, 13 February 2015
at the General Meeting
Record date in order to vote Friday, 20 February 2015
Proxy forms to be received by 14h45 Tuesday, 24 February 2015
on
General meeting of shareholders to Thursday, 26 February 2015
be held at 14h45 on
Results of the General Meeting Thursday, 26 February 2015
released on SENS on or about
Anticipated last date for the issue Thursday, 9 April 2015
by Companies and Intellectual
Property Commission “CIPC” of the
amended registration certificate
reflecting the Proposed Change of
Name
Finalisation announcement regarding Friday, 10 April 2015
the Proposed Change of Name
published on SENS
Last day to trade under the old Friday, 17 April 2015
name of Sekunjalo Investments
Limited
Shares trade under the new name of Monday, 20 April 2015
African Equity Empowerment
Investments Limited, JSE Code AEE,
ISIN ZAE000195731 and abbreviated
name “AEEI” from the commencement
of trading on
Record date for the Proposed Change Friday, 24 April 2015
of Name
Issue of replacement share Tuesday, 28 April 2015
certificates and posting thereof to
those holders of certificated
shares who have submitted their
share certificates and forms of
surrender on or before 12h00 on the
record date for the Proposed Change
of Name and updating CSDP and
broker accounts on behalf of
holders of dematerialised shares

Notes:
1. Dates and times are subject to potential changes. To the extent
that the CIPC issues the amended registration certificate
reflecting the Proposed Change of Name after Thursday, 9 April
2015, the above dates and times will be adjusted accordingly.
Any such changes will be released on SENS.
2. Share certificates in the name of Sekunjalo Investments Limited
may not be dematerialised or rematerialised after Friday, 17
April 2015.
3. If Certificated Shareholders have not yet surrendered their
share certificates on or before 12h00 on the record date for
the Proposed Change of Name, their replacement share
certificates will be posted to them within 5 (five) business
days of such surrender.

21 November 2014
Cape Town

Sponsor
PSG Capital

Date: 21/11/2014 02:30:00
Supplied by www.sharenet.co.za
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.

14/11/2014 Sekunjalo Investments Limited - Appointment Of Non-executive Director

Appointment Of Non-Executive Director

SEKUNJALO INVESTMENTS LIMITED
Incorporated in the Republic of South Africa
(Registration number: 1996/006093/06)
ISIN: ZAE000017893
JSE Share Code: SKJ
(“Sekunjalo” or “the Company” or “the Group”)

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

In accordance with paragraph 3.59(a) of the Listings Requirements of
the JSE Limited, the shareholders of the Company are hereby advised
that the board of directors of Sekunjalo (“the board”), is pleased to
announce that Ms Zenariah Barends(“Zenariah”) has been appointed as a
non-executive director of Sekunjalo effective from 14 November 2014.

The appointment of Ms Zenariah Barends is in line with the board’s
decision to appoint non-executive directors that have a strong history
of community and civil society engagement, as well as a strong
association with international and multilateral organisations and a
history of involvement with the Sekunjalo Group previously in an
executive capacity.

Zenariah is the chairperson, trustee and board member of a number of
civil society institutions including Inyathelo: The South African
Institute for Advancement and The Business Place, eKapa. She has a
long history of involvement in arts and culture through the Cape
Cultural Collective as well as a strong track record in human rights
activism. She served as Head of Investigations: Western Cape of the
Truth and Reconciliation Commission – a commission chaired by Nobel
Laureate, Archbishop Desmond Tutu.

In her current portfolio she is a senior executive and chief of staff
at Independent Media. Her portfolio includes coordinating the
involvement of the Sekunjalo Group in the BRICS Business Council and
the South Africa Saudi Arabia Business Council. She is also
responsible for coordinating the Sekunjalo Group’s various World
Economic Forum activities which include the Group’s involvement in the
Global Agenda Council on Emerging Multinationals and the Global Growth
Companies Advisory Board.

The board wishes to congratulate Zenariah on her appointment and looks
forward to her valued contributions.

14 November 2014
Cape Town
Sponsor
PSG Capital

Date: 14/11/2014 12:05:00
Supplied by www.sharenet.co.za
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.

06/11/2014 Sekunjalo Investments Limited - Changes To The Board Of Directors

Changes To The Board Of Directors

SEKUNJALO INVESTMENTS LIMITED
Incorporated in the Republic of South Africa
(Registration number: 1996/006093/06)
ISIN: ZAE000017893
JSE Share Code: SKJ
(“Sekunjalo” or “the Company” or “the Group”)

CHANGES TO THE BOARD OF DIRECTORS

In compliance with paragraph 3.59(b) and paragraph 3.59 (c) of the JSE
Limited (“JSE”) Listings Requirements, Sekunjalo hereby advises
shareholders of the following changes that are taking place to the
board of directors, with immediate effect:

- Dr M Iqbal Survé (“Dr Survé”) has tendered his resignation as
executive chairman and executive director of the Company.

The board wishes to thank Dr Survé for his dedication, leadership
and valued contribution and wish him well in his future endeavours.

- Professor Vukile Charles Mehana’s status as a non-executive
director will change from independent non-executive director to
independent non-executive chairman of the Company.

- Mr Salim Young’s status as a non-executive director will change
from lead independent non-executive to lead independent non-
executive and deputy chairman of the Company.

6 November 2014
Cape Town

Sponsor
PSG Capital

Date: 06/11/2014 05:00:00
Supplied by www.sharenet.co.za
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.

04/11/2014 Sekunjalo Investments Limited - Audited Condensed Group Results For The Year Ended 31 August 2014

Audited Condensed Group results for the year ended 31 August 2014

Sekunjalo Investments Limited
(Incorporated in the Republic of South Africa)
Registration number 1996/006093/06
Share code: SKJ and ISIN: ZAE000017893
("Sekunjalo" or "the Group" or "the Company")


Audited Condensed Group results for the year ended 31 August 2014


CONDENSED GROUP STATEMENT OF FINANCIAL POSITION


Audited Audited
Group to Group to
31 August 31 August
2014 2013
R'000 R'000

Assets
Non-current assets 971 241 726 285
Property, plant and equipment 138 266 126 890
Goodwill 55 469 37 325
Intangible assets 336 367 12 783
Investment in associate - 112 382
Loans receivable 2 065 38 763
Other financial assets 427 173 380 644
Deferred tax 11 901 17 498

Current assets 204 991 174 818
Inventory 22 305 17 765
Biological assets 36 014 41 798
Other loans receivable 245 2 275
Current tax receivable 556 174
Trade and other receivables 98 753 70 497
Cash and cash equivalents 47 118 42 309

Assets of disposal groups and non-current
assets held for sale 1 852 2 127

Total assets 1 178 084 903 230

Equity and liabilities
Capital and reserves
Share capital and share premium 403 177 403 177
Reserves 8 034 121 194
Retained income/(Accumulated losses) 157 825 (52 137)
Equity attributable to parent 569 036 472 234
Non-controlling interests 96 036 4 762
Total equity 665 072 476 996

Non-current liabilities 347 935 282 594
Other financial liabilities 135 445 149 239
Deferred tax 210 489 132 721
Other non-current liabilities 2 001 634

Current liabilities 165 077 143 640
Trade and other payables 98 873 77 848
Other financial liabilities 27 933 38 864
Other current liabilities 297 336
Provisions 26 507 21 369
Bank overdraft 4 752 1 214
Current tax payable 6 715 4 009

Total equity and liabilities 1 178 084 903 230

Net asset value (NAV) per share (cents) 115.81 96.50



CONDENSED GROUP STATEMENT OF COMPREHENSIVE INCOME


Audited Audited
Group Group
31 August 31 August
2014 2013
R'000 R'000

Revenue 620 549 569 198
Cost of sales (426 222) (390 711)
Gross Profit 194 327 178 487
Other income 4 710 3 949
Other expenses (145 590) (148 600)
Impairments (1 172) (32 913)
Fair valuation adjustments 46 303 66 193
Gain on deemed disposal of associate 22 556 -
Investment revenue 12 401 19 935
Loss from associate (6 179) (8 039)
Finance cost (19 164) (20 347)
Profit before tax 108 192 58 665
Tax (5 759) (28 313)

Profit for the year 102 433 30 352

Other comprehensive income - -
Total comprehensive income 102 433 30 352

Attributable to:
Non-controlling interests (NCI) 5 631 618
Equity holders of the parent 96 802 29 734

102 433 30 352

Earnings and diluted earnings per share (cents) 19.76 6.08




CONDENSED GROUP STATEMENT OF CHANGES IN EQUITY

Attributable Non-con-
to trolling Total
parent interests equity
R'000 R'000 R'000

Balance at 1 September 2012 442 823 9 041 451 864
Net profit for the year 29 734 618 30 352
Dividends declared to NCI by subsidiaries - (2 218) (2 218)
Changes in ownership (323) (2 580) (2 903)
Business combinations - (99) (99)
Balance at 31 August 2013 472 234 4 762 476 996
Net profit for the year 96 802 5 631 102 433
Dividends declared to NCI by subsidiaries - (1 148) (1 148)
Business combinations - 86 791 86 791

Balance at 31 August 2014 569 036 96 036 665 072


CONDENSED GROUP STATEMENT OF CASH FLOWS


Audited Audited
Group Group
31 August 31 August
2014 2013
R'000 R'000


Cash flow from operating activities 57 028 42 959

Cash flows from investing activities (30 118) (13 487)

Cash flows from financing activities (25 639) (28 063)

Increase in cash and cash equivalents 1 271 1 409

Cash and cash equivalents at beginning of the year 41 095 39 686

Cash equivalents at the end of the year 42 366 41 095



CONDENSED GROUP SEGMENTAL REPORT 2014


Technology Marine Health
Care
R'000 R'000 R'000

Revenue 184 991 315 119 22 986
External sales 184 927 314 938 22 392
Intergroup sales 64 181 594

Segment results
Operating profit/(loss) 19 711 51 234 (6 471)

Included in segment results: (899) (15 494) (2 202)
Impairments 109 - (436)
Depreciation and amortisation (1 008) (15 494) (1 766)

Carrying amount of assets 92 911 248 286 29 091
Carrying amount of liabilities 56 652 119 176 9 223

Capital expenditure 1 703 15 985 -




Bio- Enterprise
technology Investments Development Group
R'000 R'000 R'000 R'000


Revenue - 19 141 99 185 641 422

External sales - 651 97 641 620 549
Intergroup sales - 18 490 1 544 20 873

Segment results
Operating profit/(loss) (3 298) 30 568 6 834 98 578

Included in segment results: (821) 45 250 (253) 25 581
Impairments - (845) - (1 172)
Depreciation and amortisation (821) (214) (247) (19 550)
Fair valuation of investments - 46 309 (6) 46 303

Carrying amount of assets 354 164 432 937 20 695 1 178 084
Carrying amount of
liabilities 90 141 218 646 19 174 513 012
Loss from associate (6 179) - - (6 179)
Capital expenditure 9 517 68 18 282


CONDENSED GROUP SEGMENTAL REPORT 2013


Technology Marine Health
Care
R'000 R'000 R'000



Revenue 193 031 272 729 16 918
External sales 192 906 272 464 16 382
Intergroup sales 125 265 536

Segment results
Operating profit/(loss) 35 225 24 613 (9 219)
Included in segment results: (1 182) (18 217) (2 007)
Impairments (100) (1 612) -
Depreciation and amortisation (1 082) (16 605) (2 007)

Carrying amount of assets 74 904 233 829 34 784
Carrying amount of liabilities 45 935 105 169 6 896

Capital expenditure 465 9 841 713




Bio- Enterprise
technology Investments Development Group
R'000 R'000 R'000 R'000



Revenue - 24 017 88 888 595 583
External sales - 1 110 86 336 569 198
Intergroup sales - 22 907 2 552 26 385
Segment results
Operating (loss)/profit (30 494) 54 427 (7 436) 67 116

Included in segment results: (30 427) 65 078 (80) 13 165
Impairments (30 427) (779) - (32 918)
Depreciation and amortisation - (160) (256) (20 110)
Fair valuation of investments - 66 017 176 66 193

Carrying amount of assets 150 708 391 408 17 597 903 230
Carrying amount of liabilities 24 972 219 305 23 957 426 234

Loss from associate (8 039) - - (8 039)
Capital expenditure - 864 99 11 982


Reconciliation between operating profit and profit before tax



Audited Audited
Group Group
31 August 31 August
2014 2013
R'000 R'000


Operating profit 98 578 67 116
Investment revenue 12 401 19 935
Finance cost (19 164) (20 347)
Gain on deemed disposal of associate 22 556 -
Loss from equity accounted investments (6 179) (8 039)
Profit before tax 108 192 58 665





Audited Audited
Group Group
31 August 31 August
Calculation of headline earnings 2014 2013
R'000 R'000

Earnings attributable to ordinary equity
holders of parent entity - IAS 33 96 802 29 734
Adjusted for:
Gain on deemed disposal of associate
- IFRS 3 (18 350) -
Losses on disposal of property,
plant and equipment - IAS 36 100 95

Headline earnings 78 552 29 829

Number of shares in issue 491 339 489 339
Weighted number of shares in issue 489 887 489 339
Diluted number of shares in issue 489 887 489 339

Headline earnings and diluted headline
earnings per share (cents) 16.03 6.10


Business combination

African Biotechnological and Medical Innovations Investments Group holds 49.99% in Genius Biotherapeutics ("Genius").
Genius was accounted for as an associate in the prior year. As a result of change in control, Genius is now accounted
for as a subsidiary from June 2014.

In March 2014, Sekunjalo Technology Solutions Ltd (formerly Sekunjalo Health Care Ltd) through its subsidiary Saratoga,
acquired 75% of the voting rights of Afrozaar Consulting cc ("Afrozaar") which resulted in the Group obtaining control
over Afrozaar. The acquisition of Afrozaar is immaterial to the Group.




Audited Audited
Group Group
31 August 31 August
2014 2013
R'000 R'000

Property plant and equipment 11 557 135
Intangible assets 325 860 -
Deferred tax (89 367) 146
Prepayments 614 -
Loans to directors, managers and employees (676) (564)
Loans to members 11 -
Inventories 889 -
Current tax receivable 135 (14)
Trade and other receivables 395 1 951
Cash and cash equivalents 465 635
Trade and other payables (1 974) (1 893)
Loans from group companies (49 566) -
Non-controlling interest (86 775) (99)

Goodwill 18 074 3 134


Highlights

- Revenue increased by 9% from R569m to R621m.

- Operating profit increased by 47% from R67m to R99m

- Total assets increased by 30% from R903m to R1 178m.

- Headline earnings increased by 163% from R30m to R79m.

- NAV per share increased by 20% from 96.50c to 115.81c

- Net cash generated from operating activities increased by 33% from R43m to R57m.


Additional financial information

Included in the Group results, is the effect of the change in control over the Group’s Biotech investment.
This investment was previously accounted for as an associate due to certain shareholder restrictions and it was
equity accounted. The other major shareholder agrees that the Group has the power to direct and control the
relevant activities of Genius Biotherapeutics with effect from June 2014. As a result the Group has met the
definition of control of Genius Biotherapeutics in terms of IFRS 10 and it has been accounted for as a subsidiary.

The total once-off financial impact resulting from the change in control is summarised as follows:

- A gain on deemed disposal of R22,5m (R18.3m net of tax) was recognised in the Group's earnings and arose on the
deemed disposal of the investment in the associate (in terms of IFRS 3);

- The effect of the gain on deemed disposal has a once-off impact on earnings;

- The Group's NAV increased by R76m as a result of consolidating the subsidiary and the application of IFRS 3 in
terms of which the Group recognised assets, liabilities and post-acquisition earnings;

- This transaction significantly affected the Group's deferred tax with the effect of R25m being credited to earnings;
The deferred tax balance related to fair value adjustments of previous years;

- The revaluation reserve of R113m previously recognised was transferred to retained income.


Group performance

The Group revenue increased by 9% from R569m (2013) to R621m (2014), thereby reaching the next growth milestone level
of R600m revenue. This milestone reflects the further organic growth experienced in our underlying operations.

Profit before tax increased by 84% from R59m to R108m, with operating profit increasing to R99m from R67m (2013).
The profit attributable to the Group equity holders increased from R30m (2013) to R97m. Basic earnings per share
increased from 6.08c to 19.76c. Headline earnings increased from R30m to R79m, with headline earnings per share ("HEPS")
increasing from 6.10c to 16.03c.

The Group's NAV has increased by approximately 20% from R472m to R569m, which shows the consistent growth and strength
of the Group's financial position. The NAV per share increased from 96.50c to 115.81c.

Sekunjalo's strategic intent to increase its asset base has been achieved, with the Group's total assets increasing to
over the billion rand benchmark to R1 178m.

Net cash generated from operating activities increased from R43m (2013) to R57m (2014), mainly as a result of organic
growth in the underlying operations. The majority of the underlying operations contributed positively to this result.

The once-off financial effect of the change in control of Genius Biotherapeutics must be considered when reviewing
the results. The detail has been provided in the additional financial information paragraph above.

Strategic investments

The Group's strategic investments consist of British Telecom Communication Services South Africa ("BTSA"), Saab
South Africa (Pty) Ltd ("Saab SA") and Pioneer Food Group Ltd.

The investment in British Telecoms had been financed via a preference share and this was fully settled and paid for
during the current year under review by utilising dividend income generated by the investment. The dividend returns
from this investment is expected to continue in the foreseeable future.

Saab SA is the South African operations of Swedish multi-national Saab AB, which specialises in civil security
and defence. The Group expects this investment to return a dividend in the medium to long term.

Our investment in the JSE-listed Pioneer Foods Group increased from R126m to R189m for our 0,75% stake. Dividends
of R2,4m were received in the current year.


Information Communication Technology

The Sekunjalo Technology Solutions Group ("Sekunjalo TSL") has shown an expected marginal decline in revenue of 5%
from R193m to R185m due to the completion and implementation of certain laboratory systems projects during the
past 18 months and of which the projects have now moved to annuity maintenance income.

Sekunjalo TSL achieved a solid operating profit of R19.6m.

The subsidiary companies of Sekunjalo TSL include Saratoga Software (Pty) Ltd ("Saratoga"), which is a software
development house primarily focused on the financial industry, and Digital Matter (Pty) Ltd ("Digital Matter"), a
75% Saratoga-owned subsidiary providing mobile data solutions. In the prior year Saratoga acquired World Wide
Creative (Pty) Ltd ("World Wide Creative"), a digital marketing agency, to expand its operations into a new sector.
During the current year, Saratoga also acquired 75% of Afrozaar, which focuses on digital media, and content
redistribution.

Health System Technologies ("HST") is a leading provider of Hospital Information and Laboratory Information Systems
for the South African and African public sector and continues to show sustainable and profitable results with ongoing
maintenance annuity income from its IT contracts and projects over the past few years.

HST has partnered with AME International through AmetHst (Pty) Ltd ("AmetHst"), which had won previously the Gauteng
Department of Health's hospital information systems ("HIS") contract, which entailed the implementation of HIS systems
in over 60 Gauteng hospitals and clinics.

However, as previously reported, the contract entered into between AmetHst, as part of the Baoki Consortium, and the
Gauteng Department of Health for the implementation of HIS has been cancelled by the Baoki Consortium.

We wish to notify shareholders that our legal claim against the department has been withdrawn due to complex
investigations into the matter. The counter claim by the department against Baoki still exists, however we have
confirmed via our legal advisors that any liability that may exist is contained with AmetHst (Pty) Ltd only.
We have furthermore ascertained that there is no risk of any claims against either the directors of the company,
its shareholders or the Group in any way.

The operating profit contains non-recurring provisions and costs relating to warranty settlement payments for both
World Wide Creative and Afrozaar as well as a non-recurring guarantee payment for settling the AmetHst overdraft
which has been recorded during the current year.


Marine

Premier Fishing SA (Pty) Ltd ("Premier Fishing") is the largest black-owned and controlled fishing company in South
Africa and the most transformed in terms of its management and employees. The major product lines for Premier Fishing
are south coast rock lobster, west coast rock lobster, squid, abalone and pelagic.

Premier Fishing had a bumper year with excellent sales volumes and market prices in the lobster, pelagic and abalone
sectors. This is reflected in the Marine division increasing its turnover by 16% from R272m (2013) to R315m.

Operating profit increased by 112% from R24m (2013) to R51m. This good performance was achieved due to improved
operational efficiencies.

The Marine division experienced exceptional catch rates through effective planning, and vessel scheduling and
utilisation also contributed to the excellent performance.

The south coast rock lobster division performed considerably well taking into account extra sales volumes and
good catch rates. The west coast rock lobster division, however, experienced a decline in revenue. This resulted
from industry-wide lower catch rates and sales volumes but was counteracted through better market prices and
collaboration with fishing communities as well as the effects of the fluctuation of the rand,

The pelagic sector fared well in the 2014 season by achieving good catch rates. This division landed the majority
of its pilchard quota and a significant portion of its anchovy quota.

As an industry, the squid sector did not fare well during the 2014 fishing season due to poor catch rates. This
division experienced a small loss which has been contained. This is, however, not a material part of our
Marine division.

Marine Growers (Pty) Ltd, a subsidiary of Premier Fishing, sold additional volumes of abalone to the Far East,
hence achieving greater revenues. The abalone farm continues to perform efficiently and consistently despite
the tough economic climate.


Health Care

The companies under the Health Care division, Sekpharma (Pty) Ltd and Wynberg Pharmaceuticals (Pty) Ltd, focus
on ethical and consumer products as well as the production of natural products to promote health and hygiene and
food security in the agricultural and food processing sectors.

Revenue for the Health Care division has increased by 32% from R17m to R22m. This increase relates to a change
in the sales and distribution model adopted during the year and by expanding the company's customer base for
natural disinfectants and sanitisers.

Both revenue and cash generation from this operation continue to improve year on year.


Biotechnology

Genius Biotherapeutics ("Genius"), formerly known as Bioclones (Pty) Ltd, is South Africa and Africa's largest
medical biotechnology company, with strategic interests in biogenerics and novel compounds.

Genius also holds global patents for personalised medicine and vaccines. Genius Biotherapeutics' novel technology
is in advanced stages of development and will soon be proceeding to Phase 1 clinical trials. The company partnered
with the University of Cape Town's ("UCT") Department of Medicine, UCT Lung Institute and Pulmonology and Immunity
unit to develop the therapeutic Dendritic Cell Vaccine ("DCV") against cancer.

Management continues with its plans to upgrade the manufacturing facility to increase efficiency at the facility
in Centurion. The scientific team at the Cape Town facility also updated its protocol to produce biologically
active granulocyte-colony stimulating factor (G-CSF) technology.


Enterprise development

Sekunjalo Media ("Sekmedia") achieved its turnaround by completing the implementation of its strategy to return
to company Events Social Marketing and Productions Afrika (Pty) Ltd ("espAfrika") to profitability from a R7m operating
loss in 2013 to a R7,7m operating profit in the 2014 financial year. Sekmedia owns the rights of and manages the Cape
Town International Jazz Festival. The Cape Town International Jazz Festival continues to bear fruit and contributes
greatly to the gross domestic product (GDP) of the Western Cape and the national economy.


Basis of preparation

The condensed consolidated financial statements are prepared in accordance with the requirements of the JSE Limited
Listings Requirements for provisional reports, and the requirements of the Companies Act of South Africa, as amended,
applicable to summary financial statements. The Listings Requirements require provisional reports to be prepared in
accordance with the framework concepts and the measurement and recognition requirements of International Financial
Reporting Standards (IFRS) and the SAICA Financial Reporting Guides as issued by the Accounting Practices Committee
and Financial Pronouncements as issued by the Financial Reporting Standards Council and to also, as a minimum, contain
the information required by IAS 34 Interim Financial Reporting. The accounting policies applied in the preparation of
the consolidated financial statements from which the condensed financial statements were derived are in terms of
International Financial Reporting Standards and are consistent with those accounting policies applied in the preparation
of the previous consolidated annual financial statements, apart from the adoption of the standards listed below.

IFRS 10 ­ Consolidated financial statements
IFRS 11 ­ Joint arrangements
IFRS 12 ­ Disclosure of interest of other entities
IFRS 13 ­ Fair value measurement

As a result of adopting IFRS 10, the Group changed its accounting policy for assessing control over its investees. IFRS 10
introduces a new definition of control which requires the investor to assess control by referring to the investor's exposure
or rights to variable returns for its involvement with the investee and the ability to use its power to affect those returns.

The group applied the transitional provision of IFRS 10 and determined that they had control over the investment in Genius
Biotherapeutics from June 2014, the effective date that control changed.

In terms of IFRS 11, proportionate consolidation for joint ventures is no longer permitted. Joint arrangements that meet the
definition of a joint venture must be accounted for using the equity method. The Group has now applied IFRS 11 in accordance
with the transitional provisions which did not affect the current year’s results.

IFRS 12 is a disclosure standard requiring a wide range of disclosures about an entity's interests in subsidiaries, joint
arrangements, associates and unconsolidated 'structured entities'. The standard also requires disclosures about judgements
made by an entity to determine whether it controls another entity. The Group has included additional disclosure as prescribed
by the standard.

IFRS 13 establishes a single framework for measuring fair value and making disclosures about fair value measurement, when
such measurements are required by other IFRSs. The revised definition of fair value is the price at which a transaction
to sell an asset or transfer a liability would take place between market participants at the measurement date. The Group
included additional disclosure as prescribed by this standard.


This summarised report is extracted from audited information, but is not audited itself. The annual financial statements
were audited by Grant Thornton (Cpt) Inc., who expressed an unmodified opinion thereon. The audited annual financial
statements and the auditor's report thereon are available for inspection at the company's registered office. The auditor's
report does not necessarily report on all of the information contained in this announcement. Shareholders are therefore
advised that in order to obtain a full understanding of the nature of the auditor's engagement they should obtain a copy
of the auditor's report together with the accompanying financial information from the issuer's registered office.

The directors take full responsibility for the preparation of the provisional condensed consolidated financial results and
that the financial information has been correctly extracted from the underlying annual financial statements. This financial
information has been prepared under the supervision of Natasha September, Financial Controller, BCom (Hons), CA(SA).


Events post reporting date

The directors are not aware of any events post reporting date that materially affects the Group.


Future prospects

Our strategic intent to increase value in our core operational investments in our technology, marine, health care and
biothechnology and enterprise development sectors has shown excellent growth during the current year and the Group built
a strong platform for further growth over the next few years.

As we continue to build on our financial successes we believe that Sekunjalo is well positioned to further enhance
its earnings and is well set to further bolster its asset and net asset value through organic growth, acquisitions and
strategic initiatives.

Any reference to future financial performance included in this announcement has not been reviewed or reported on by the
Group's auditors.


Dividends

The Board of directors is pleased to announce that it has approved and declared a gross final dividend of 2 cents per
share for the year ended 31 August 2014 from income reserves. The final dividend amount, net of South African dividend
tax of 15% which equates to 0.3 cents per share, is therefore a net 1.7 cents per share for those shareholders that are
not exempt from Dividend Tax. The company will not be utilising any credits that relate to secondary tax on companies.

The number of ordinary shares in issue at the declaration date is 491 339 434 and the income tax number of the company
is 9314001034.


The salient dates of this dividend distribution are:

Last day to trade cum dividend Friday, 13 February 2015
Trading ex dividend commences Monday, 16 February 2015
Record date Friday, 20 February 2015
Date of payment Monday, 23 February 2015


Share certificates may not be dematerialised or rematerialised between Monday, 16 February 2015, and Friday, 20 February 2015,
both days inclusive.


Proposed change of name

Shareholders are hereby advised that, due to strategic reasons, the Board of directors have proposed that the name of the
Company be changed to African Equity Empowerment Investments Limited, subject to shareholder approval at a general
meeting ("Proposed Change of Name").

The rationale and reason for the Proposed Change of Name is to better reflect the underlying businesses and maximising the
investments and opportunities of Sekunjalo going forward and to differentiate the Company from its private holding company.


A circular providing detailed information, as required, in respect of the Proposed Change of Name will be distributed to
Sekunjalo shareholders on or about Friday, 21 November 2014 and the relevant details will also be announced on SENS at the
appropriate time.


Appreciation

We would like to thank the Sekunjalo Board of directors for its continued strategic guidance, wise stewardship and
commitment in ensuring the continued success of the Sekunjalo Group.

In addition, we would also like to express our sincere gratitude and appreciation to all our executives, our team of
highly talented employees and strategic partners for their passion, loyalty and dedication for their efforts as they
continue to contribute to the success of Sekunjalo.



MI Survé K Abdulla
Executive chairman Chief executive officer (CEO)


4 November 2014


Directors:
*Dr M Iqbal Survé (Executive Chairman); *Khalid Abdulla (CEO); Prof Vukile Mehana; Johannes Mihe Gaomab; Salim Young;
*Cherie Felicity Hendricks; *Chantelle Ah Sing; Aziza Amod; Takudzwa Hove
*Executive directors

Company secretary:
Carmelita Arendse

Registered address:
Quay 7, East Pier, Victoria and Alfred Waterfront, Cape Town, 8001,

Email:
carmen@sekunjalo.com

Transfer secretaries:
Link Market Services South Africa (Pty) Ltd
Rennie House, 13th Floor, 19 Ameshoff Street, Braamfontein, 2001

Auditors:
Grant Thornton (Cpt) Inc, Cape Town

Sponsor:
PSG Capital (Pty) Ltd, Stellenbosch

Date: 04/11/2014 04:00:00
Supplied by www.sharenet.co.za
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.

04/11/2014 Sekunjalo Investments Limited - Further Trading Statement

Further trading statement

Sekunjalo Investments Limited
(Incorporated in the Republic of South Africa)
(Registration number 1996/006093/06)
Share code: SKJ & ISIN: ZAE000017893
("Sekunjalo" or "the Company" or “the Group”)

FURTHER TRADING STATEMENT

Shareholders are referred to the SENS announcement dated 30
October 2014 and are hereby advised that a reasonable degree
of certainty exists that the Company now expects that the
Group’s headline earnings per share for the year ended 31
August 2014 will be between 15.42 cents and 16.64 cents per
share compared to the 6.10 cents in the prior year, an
increase of between 153% and 173%.

The abovementioned financial information on which this further
trading statement is based has not been reviewed or reported
on by the Company’s auditors. The annual financial results of
Sekunjalo are expected to be released on SENS on or about 4
November 2014.

Cape Town
4 November 2014

Sponsor
PSG Capital

Date: 04/11/2014 02:05:00
Supplied by www.sharenet.co.za
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.

30/10/2014 Sekunjalo Investments Limited - Trading Statement

Trading Statement

Sekunjalo Investments Limited
(Incorporated in the Republic of South Africa)
(Registration number 1996/006093/06)
Share code: SKJ & ISIN: ZAE000017893
("Sekunjalo" or "the Company" or “the Group”)

TRADING STATEMENT

In terms of the Listings Requirements of the JSE Limited, a
listed company is required to publish a trading statement as
soon as it is satisfied that a reasonable degree of certainty
exists that its financial results for the current reporting
period will differ by 20% or more compared to the same period
in the prior year.

Sekunjalo shareholders are hereby advised that it is expected
that the Group’s headline earnings per share for the year
ended 31 August 2014 will be between 19.11 cents to 20.33
cents per share compared to the 6.10 cents in the prior year,
an increase of between 213% and 233%.

Shareholders are further advised that it is expected that the
Group’s basic earnings per share for the year ended 31 August
2014 will be between 19.09 cents to 20.31 cents compared to
6.08 cents in the prior year, being an increase of between
214% and 234%.

The abovementioned financial information on which this trading
statement is based has not been reviewed or reported on by the
Company’s auditors. The annual financial results of Sekunjalo
are expected to be released on SENS on or about 4 November
2014.

Cape Town
30 October 2014

Sponsor
PSG Capital

Date: 30/10/2014 04:32:00
Supplied by www.sharenet.co.za
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.

08/09/2014 Sekunjalo Investments Limited - Change Of Company Secretary

Change Of Company Secretary

Sekunjalo Investments Limited
(Incorporated in the Republic of South Africa)
(Registration number 1996/006093/06)
Share code: SKJ
ISIN: ZAE000017893
(“Sekunjalo” or “the Company”)

CHANGE OF COMPANY SECRETARY

In accordance with paragraph 3.59(a) and (b) of the Listings
Requirements of the JSE Limited, shareholders are hereby advised
of the following changes in relation to the Company Secretary of
the Company:

1. Ms Cherie Hendricks has resigned as Company Secretary with
immediate effect; and

2. Mrs Carmelita Arendse has been appointed as the new Company
Secretary with effect immediate effect.

8 September 2014
Cape Town

Sponsor
PSG Capital

Date: 08/09/2014 10:00:00
Supplied by www.sharenet.co.za
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.

10/07/2014 Sekunjalo Investments Limited - Dealing In Shares By An Associate Of A Director And Disclosure Of Acquisition Of Securities

Dealing In Shares By An Associate Of A Director And Disclosure Of Acquisition Of Securities

Sekunjalo Investments Limited
(Incorporated in the Republic of South Africa)
(Registration number 1996/006093/06)
Share code: SKJ
ISIN: ZAE000017893
(“Sekunjalo” or “the Company”)

DEALING IN SEKUNJALO INVESTMENTS LIMITED SHARES BY AN ASSOCIATE OF A
DIRECTOR AND DISCLOSURE OF ACQUISITION OF SECURITIES

In compliance with rules 3.63 to 3.74 of the JSE Limited’s Listings
Requirements, the following information is disclosed:

NAME OF DIRECTOR MI Surve
COMPANY OF WHICH I AM A DIRECTOR Sekunjalo Investments Limited
STATUS:EXECUTIVE/NON-EXECUTIVE Executive
TYPE OF SECURITIES Shares
CLASS OF SECURITIES Ordinary
DATE OF TRANSACTION 10 July 2014
CENTS PER SHARE 50
NUMBER OF SECURITIES TRANSACTED 14 670 000
TOTAL RAND VALUE OF SECURITIES R7 335 000.00
NAME OF ASSOCIATE Sekunjalo Investment Holdings
(Pty) Ltd
RELATIONSHIP WITH DIRECTOR Director is a director of the
associate
NATURE OF TRANSACTION Purchase (Off-market transaction)
NATURE AND EXTENT OF INTEREST IN Indirect non-beneficial
THE TRANSACTION
CLEARANCE OBTAINED Yes

In accordance with section 122(3)(b) of the Companies Act, No. 71 of 2008
and section 3.83(b) of the JSE Limited’s Listings Requirements,
shareholders are hereby advised that the Company has received a formal
notification in the prescribed form that Sekunjalo Investment Holdings
(Pty) Ltd has acquired an interest in the securities of the Company and as
such the total interest in the securities of the Company held by Sekunjalo
Investment Holdings (Pty) Ltd is now 57.28% of the total issued “B”
ordinary share capital of the Company.

Cape Town
10 July 2014

Sponsor
PSG Capital

Date: 10/07/2014 10:52:00
Supplied by www.sharenet.co.za
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.

07/07/2014 Sekunjalo Investments Limited - Dealing In Sekunjalo Investments Limited Shares By An Associate Of Director And Disclosure Of Disposal Of Securities

Dealing In Sekunjalo Investments Limited Shares By An Associate Of Director And Disclosure Of Disposal Of Securities

Sekunjalo Investments Limited
(Incorporated in the Republic of South Africa)
(Registration number 1996/006093/06)
Share code: SKJ
ISIN: ZAE000017893
(“Sekunjalo” or “the Company”)

DEALING IN SEKUNJALO INVESTMENTS LIMITED SHARES BY AN ASSOCIATE OF
DIRECTOR AND DISCLOSURE OF DISPOSAL OF SECURITIES

In compliance with rules 3.63 to 3.74 of the JSE Limited’s Listings
Requirements, the following information is disclosed:

NAME OF DIRECTOR K Abdulla
COMPANY OF WHICH I AM A DIRECTOR Sekunjalo Investments Limited
STATUS:EXECUTIVE/NON-EXECUTIVE Executive
TYPE OF SECURITIES Shares
CLASS OF SECURITIES Ordinary
DATE OF TRANSACTION 07 July 2014
CENTS PER SHARE 58
NUMBER OF SECURITIES TRANSACTED 10 231 708
TOTAL RAND VALUE OF SECURITIES R5 934 390.64
NAME OF ASSOCIATE The Fisk Trust
RELATIONSHIP WITH DIRECTOR Director is a trustee of the
associate
NATURE OF TRANSACTION Disposal (Off-market transaction)
NATURE AND EXTENT OF INTEREST IN Indirect non-beneficial
THE TRANSACTION
CLEARANCE OBTAINED Yes

In accordance with section 122(3)(b) of the Companies Act, No. 71 of 2008
and section 3.83(b) of the JSE Limited’s Listings Requirements,
shareholders are hereby advised that the Company has received a formal
notification in the prescribed form that The Fisk Trust has disposed of an
interest in the securities of the Company, in accordance with The Fisk
Trust’s funding agreement and as such the total interest in the securities
of the Company held by The Fisk Trust is now 2.81% of the total issued “B”
ordinary share capital of the Company.

Cape Town
07 July 2014

Sponsor
PSG Capital

Date: 07/07/2014 12:33:00
Supplied by www.sharenet.co.za
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.

27/05/2014 Sekunjalo Investments Limited - Dealing In Sekunjalo Investments Limited Shares By An Associate Of A Director

Dealing In Sekunjalo Investments Limited Shares By An Associate Of A Director

Sekunjalo Investments Limited
(Incorporated in the Republic of South Africa)
(Registration number 1996/006093/06)
Share code: SKJ
ISIN: ZAE000017893
(“Sekunjalo” or “the Company”)

DEALING IN SEKUNJALO INVESTMENTS LIMITED SHARES BY AN ASSOCIATE OF A
DIRECTOR

In compliance with rules 3.63 to 3.74 of the JSE Limited’s Listings
Requirements, the following information is disclosed:

NAME OF DIRECTOR MI Surve
COMPANY OF WHICH I AM A DIRECTOR Sekunjalo Investments Limited
STATUS:EXECUTIVE/NON-EXECUTIVE Executive
TYPE OF SECURITIES Shares
CLASS OF SECURITIES Ordinary
DATE OF TRANSACTION 23 May 2014
CENTS PER SHARE 42
NUMBER OF SECURITIES TRANSACTED 2 000 000
TOTAL RAND VALUE OF SECURITIES R840 000.00
NAME OF ASSOCIATE Haraas Trust
RELATIONSHIP WITH DIRECTOR Director is a trustee of the
associate
NATURE OF TRANSACTION The conversion of unlisted A class
ordinary shares to listed B class
ordinary shares. The A class
ordinary shares are converted at
their original issue price on 13
April 1999. (Off-market
transaction)
NATURE AND EXTENT OF INTEREST IN Indirect, non-beneficial
THE TRANSACTION
CLEARANCE OBTAINED Yes


Cape Town
27 May 2014

Sponsor
PSG Capital

Date: 27/05/2014 09:00:00
Supplied by www.sharenet.co.za
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.